# In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide

## TL;DR

RW01, a cyclic peptide, enhances tetracycline effectiveness against Pseudomonas aeruginosa by increasing membrane permeability and reducing resistance.

## Contribution

RW01 synergizes with tetracyclines to overcome resistance in Pseudomonas aeruginosa via membrane permeabilization.

## Key findings

- RW01 synergizes with tetracyclines, reducing minimum inhibitory concentrations up to 16-fold.
- Resistance to RW01-minocycline involves pmrB gene mutations affecting outer membrane composition.
- RW01 reduces mutant prevention concentration of minocycline and shows no in vivo toxicity in mice.

## Abstract

The pipeline for new drugs against multidrug-resistant Pseudomonas aeruginosa remains limited, highlighting the urgent need for innovative treatments. New strategies, such as membrane-targeting molecules acting as adjuvants, aim to enhance antibiotic effectiveness and combat resistance. RW01, a cyclic peptide with low antimicrobial activity, was selected as an adjuvant to enhance drug efficacy through membrane permeabilization. RW01’s activity was evaluated via antimicrobial susceptibility testing in combination with existing antibiotics on 10 P. aeruginosa strains and analog synthesis. Synergy was assessed using checkerboard assays, and one-step mutants were generated to identify altered pathways through whole-genome sequencing and variant analysis. Permeabilizing activity was studied using flow cytometry and real-time fluorescence measurement. In vivo toxicity was assessed in female C57BL/6J mice, and possible interaction with mouse serum was also evaluated. Susceptibility testing revealed specific synergy with tetracyclines, with up to a 16-fold reduction in minimum inhibitory concentrations. Sequencing revealed that resistance to the RW01-minocycline combination involved mutations in the pmrB gene, affecting outer membrane lipopolysaccharide composition. This was further confirmed by the identification of cross-resistance to colistin in these mutants. RW01 reduced the mutant prevention concentration of minocycline from 64 to 8 mg/L. RW01 was demonstrated to enhance membrane permeabilization and therefore minocycline uptake with statistical significance. Synthetic derivatives of RW01 showed a complete loss of activity, highlighting the importance of RW01’s D-proline(NH2) residue. No acute or cumulative in vivo toxicity was observed in mice. These findings suggest that RW01 could revitalize obsolete antimicrobials and potentially expand therapeutic options against multidrug-resistant P. aeruginosa.